Nuventra Pharma Sciences: Detailed Company Information & Corporate Profile

Contact top employees from Nuventra Pharma Sciences

Summary

Nuventra Pharma Sciences is a private company that has been in the industry for 18 years. The company currently specializes in the Pharmaceuticals, Pharmaceuticals, Biotechnology, Medical Research & Laboratories areas. The position of the CEO is occupied by Geoffrey Banks. Its headquarters is located at Durham, North Carolina, USA. The number of employees ranges from 25 to 100. The annual revenue of Nuventra Pharma Sciences varies between 1 and 10M. To connect with Nuventra Pharma Sciences employee register on SignalHire.

Nuventra Pharma Sciences Websitenuventra.com
Social Links
facebooktwitterlinkedIn
Phone Number888-615-5111
Industries
Nuventra Pharma Sciences Headquarters address2525 Meridian Pwky, Research Triangle Park, NC, 27713 US
Company Size100-200 employees
SpecialtiesPharmacokinetics (PK) / Pharmacodynamics (PD), Clinical Pharmacology, Population Pharmacokinetics (popPK), Medical/Scientific Writing, Regulatory Representation, Pre- IND, IND, NDA Support, Toxicokinetics, Phase 1 Clinical Ops Support, Model Based Drug Development
SIC Code8000
DMA CodeResearch Triangle
Founded2008
Estimated Annual Revenue$1 - 10M
Operating StatusAcquired

Competitors

Name
Founded
Type
Employees
Revenue
Funding
1994Privately
Held
100 - 250 32.9M $0
2006Privately
Held
25 - 100 2.1M $0
1990Privately
Held
500 - 1.0K 73.5M $0
-- 10000+ - $-

Workforce Turnover

Length of Employment

arrow

Nuventra Pharma Sciences's workforce includes employees across a wide range of tenure levels.

14% have been with the company for 3 to 4 years29% have been with the company for 5 to 7 years21% have been with the company for 8 to 10 years36% have been with the company for more than 11 years
Contact top employees from Nuventra Pharma Sciences
Michael Lamson
Michael LamsonVice President, Pharmacokinetics and Clinical Pharmacology
Phone (1)
+1-***-***-1575
Unlock contacts
Elizabeth Potocka
Elizabeth PotockaSenior Consultant, Clinical Pharmacology and Pharmacokinetics
Email (4)
e******a@nuventra.com , e***************a@novartis.com , e***************a@gmail.com , ...
Phone (3)
+1-870-***-**39 , +1-323-***-**45 , ...
Unlock contacts
Anthony Destefano
Anthony DestefanoSr. Bioanalytical Consultant
Email (4)
a********o@nuventra.com , *j*@usp.org , a***************o@allucent.com , ...
Phone (3)
+1-480-***-**82 , +1-909-***-**38 , ...
Unlock contacts
David Sorscher
David SorscherSenior Director, Scientific Writing and Regulatory Affairs
Unlock contacts
George Dukes
George DukesSenior Consultant
Email (5)
g**********s@gsk.com , g****s@nuventra.com , g************s@gsk.com , ...
Phone (1)
+1-***-***-4266
Unlock contacts
Lindsey Webster
Lindsey WebsterSenior Manager, Project Management and Pharmacokinetics Specialist
Unlock contacts
Bill Wargin
Bill WarginChief Purveyor of Pharmacokinetic Information
Phone (1)
+1-***-***-7667
Unlock contacts

Nuventra Pharma Sciences Corporate Information: FAQ

Nuventra Pharma Sciences operates in the Pharma industries. More details can be found on the official website: nuventra.com.
The headquarters of Nuventra Pharma Sciences are located in Research Triangle Park, United States.
The current CEO of Nuventra Pharma Sciences is Geoffrey Banks
You can contact Nuventra Pharma Sciences by phone at 888-615-5111.
Nuventra Pharma Sciences currently employs 100-200 people.
Nuventra Pharma Sciences's revenue is approximately 3.7M.
Well-known competitors of Nuventra Pharma Sciences include BridgeHead Software, Anoixis Corporation, Quotient Sciences and Pharmaspectra.

Data Privacy

GDPR Icon

GDPR COMPLIANT

SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.

CCPA Icon

CCPA COMPLIANT

SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.

BACK TO TOP